Immune-checkpoint inhibitors (ICIs) have dramatically improved the survival of patients with certain forms of cancer; however, these agents also have adverse effects that are often quite different to those of more traditional cancer therapies. In this Review, the authors describe the epidemiology, treatment and management of the various immune-related adverse events that can occur in patients…
Nature Reviews Clinical Oncology – Recent results from the phase III AQUILA trial demonstrate the benefit of fixed-duration monotherapy with daratumumab over observation in patients…
Nature Reviews Clinical Oncology – Recent results from the phase III AQUILA trial demonstrate the benefit of fixed-duration monotherapy with daratumumab over observation in patients…
Nature Reviews Clinical Oncology – Recent results from the phase III AQUILA trial demonstrate the benefit of fixed-duration monotherapy with daratumumab over observation in patients…
Nature Reviews Clinical Oncology – Adding brentuximab vedotin to lenalidomide and rituximab improves OS in R/R DLBCL
Nature Reviews Clinical Oncology – Analysis of circulating tumour DNA (ctDNA) is commonly used for molecular profiling in patients with advanced-stage non-small-cell lung cancer (NSCLC).…
Nature Reviews Clinical Oncology – Tumour-infiltrating lymphocytes (TILs) are crucial effectors of the anticancer immune response and are hypothesized to be key determinants the efficacy…
Nature Reviews Clinical Oncology – Despite lower levels of most targetable alterations, a strong association with a history of smoking and generally higher levels of…
Nature Reviews Clinical Oncology – Women with clinically node negative breast cancer can safely avoid axillary surgery
Nature Reviews Clinical Oncology – cfDNA screening for fetal aneuploidy facilitates maternal cancer detection
Nature Reviews Clinical Oncology – Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL
